Skip to content
OpenCapital
Get started

Haemonetics HAE Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied at other companies

Medtronic logo
MedtronicMDT
——
Danaher logo
DanaherDHR
——
Baxter International logo
Baxter InternationalBAX
——
Fortive logo
FortiveFTV
——

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied?
Haemonetics (HAE) reported remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied of $36.6M in Q4 2025.
How has Haemonetics's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied changed year-over-year?
Haemonetics's remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied increased by 9.9% year-over-year, from $33.3M to $36.6M.